Recent advances in the understanding of CRC inter-tumor heterogeneity have led to substantial improvements in the therapeutic strategies utilized to treat CRC patients [4–6] One notable example is how tumors are screened for KRAS, NRAS, and BRAF mutations to determine eligibility for anti-EGFR monoclonal antibody treatment [5, 6]. This evidence concerns the gene EGFR and colorectal carcinoma.